Molecular Imaging: Page 34

Telix secures Czech approval for prostate PET radiopharmaceutical
By AuntMinnieEurope.com staff writers
Telix Pharmaceuticals has received approval from the Czech Republic's Ministry of Health for use of its Illuccix radiopharmaceutical for prostate cancer PET imaging in that country.
February 18, 2021
2021 02 19 01 09 5836 Cancer Cells Prostate 400
Spanish researchers tie midlife heart disease to Alzheimer's
By Brian Casey
Researchers from Spain have used PET to discover that individuals in their 50s with signs of cardiovascular disease also have reduced brain metabolism in areas connected with Alzheimer's disease. The findings provide a link between brain and heart health.
February 16, 2021
2020 05 20 16 37 3471 Brain Abstract 400
Nano-MRI outduels PSMA-PET/CT for prostate cancer
By Wayne Forrest
Clinicians looking to accurately classify suspicious lymph nodes in prostate cancer patients could have another effective noninvasive option with a unique contrast-enhanced MR imaging technique, according to a study published online on 30 January in the Journal of Nuclear Medicine.
February 11, 2021
One set of images (A) shows a 7-mm diameter lymph node that is positive on both nano-MRI and PSMA-PET/CT in a patient's left pararectal region. For comparison, the other set of images (B) shows a 4-mm diameter lymph node diagnosed as positive on nano-MRI (left) but negative on PSMA-PET/CT (right) with no Ga-68 PSMA tracer uptake in the region (green circle). Images courtesy of the Journal of Nuclear Medicine.
Russians eye radiopharmaceuticals with metal
By AuntMinnieEurope.com staff writers
Metal-containing radiopharmaceuticals are highly effective at detecting early markers of Alzheimer's disease, and they are synchrotron-independent and long-lived, according to a new review by Russian researchers.
February 10, 2021
2018 07 24 22 17 0515 Brain 400
EANM launches extremity dose survey
By AuntMinnieEurope.com staff writers
The European Association of Nuclear Medicine (EANM) has launched a survey to explore how different European countries use nuclear medicine extremity dose guidelines and dosimeters.
February 7, 2021
2021 01 29 17 35 3623 Eanm 400
Aikido invests in U.K. prostate radiopharma firm
By AuntMinnieEurope.com staff writers
Aikido Pharma has made an investment in Convergent Therapeutics, a company developing a radiopharmaceutical for treating prostate cancer. Aikido made the investment in the form of a $2 million (1.7 million euros) convertible promissory note purchase agreement.
February 2, 2021
2019 05 03 20 23 2154 Prostate 3 D 400
Higher radiation can improve outcome in lung cancer
By Rebekah Moan
Dutch and U.S. groups reported new research findings from two studies about the use of higher radiation boost doses for lung cancer at the International Association for the Study of Lung Cancer world conference. The virtual event wrapped up on 31 January.
February 2, 2021
2021 02 02 17 39 1965 Lung Cancer Ct 3d 400
EANM unveils supplier audit initiative
By AuntMinnieEurope.com staff writers
The European Association of Nuclear Medicine (EANM) Research has launched a supplier audit program, along with three new PET/CT accreditations.
January 28, 2021
2021 01 29 17 35 3623 Eanm 400
Whole-body MRI on par with PET/CT for myeloma
By AuntMinnieEurope.com staff writers
U.K. researchers found that whole-body MRI was more sensitive for assessing bone lesions in multiple myeloma than F-18 FDG-PET/CT but did not result in a statistically significant difference in patient management, according to results published on 19 January in the European Journal of Nuclear Medicine and Molecular Imaging.
January 21, 2021
2020 08 20 17 11 3220 Mri Scanner2 400
Danish hospital images 1st patient with PET water device
By AuntMinnieEurope.com staff writers
Aarhus University Hospital in Denmark imaged its first patients with MedTrace Pharma's device for oxygen-15 PET imaging to measure myocardial blood flow.
January 17, 2021
2020 03 09 20 45 0805 Pet Ct Machine 400
Blue Earth buys therapeutic rights to rhPSMA technology
By AuntMinnieEurope.com staff writers
Bracco molecular imaging subsidiary Blue Earth Diagnostics has acquired exclusive, worldwide rights to therapeutic applications of radiohybrid prostate-specific membrane antigen (rhPSMA) technology developed by German radiopharmaceutical firm Scintomics and the Technical University of Munich.
January 4, 2021
2019 12 19 00 53 5252 Hands Shaking Deal 400
What impact will Brexit deal have on radiology?
By Steve Holloway
The protracted political, economic, and regulatory game of chess played by London and Brussels finally came to an end when the U.K. and European Union's Trade and Cooperation Agreement was signed on 24 December. Market columnist Steve Holloway assesses the implications of the Brexit deal.
January 4, 2021
2021 01 04 20 51 5371 Brexit Chess 400
Previous Page
Page 34 of 120
Next Page